DoD Breast Cancer, Breakthrough Award Level 4 | W81XWH 21 BCRP BTA4 2

Opportunity Information: Apply for W81XWH 21 BCRP BTA4 2

The DoD Breast Cancer Research Program (BCRP) Breakthrough Award Level 4 (Funding Opportunity Number W81XWH-21-BCRP-BTA4-2) is designed to back ambitious breast cancer research that has a realistic shot at producing a true breakthrough rather than an incremental improvement. The central expectation is impact: proposed work should plausibly transform how breast cancer is prevented and/or clinically managed, and it should aim for an approach that is fundamentally better than what is already approved or currently moving through clinical development. Applicants are also expected to be explicit about which breast cancer patient groups, or which at-risk populations, would ultimately benefit if the project succeeds, keeping the research anchored to real-world clinical need.

This opportunity is specifically for Funding Level 4, which sits at the most advanced end of the Breakthrough Award structure. The program has four levels total, each meant to match different stages on the path to clinical application, and investigators are responsible for choosing the correct level based on scope rather than budget size. A key point is that proposals that do not meet Level 4 intent will not be recommended for funding even if they would have fit Levels 1 through 3, which are offered under separate announcements. In other words, Level 4 is not simply “a bigger project”; it is a distinct category focused on large, practice-changing clinical efforts.

Level 4 projects must be large-scale and explicitly intended to transform or revolutionize clinical management and/or prevention of breast cancer, and they must include a human clinical trial as a required component. The program expects the Principal Investigator to demonstrate the capacity to run a complex clinical project, either through direct experience leading large initiatives or through a firm, credible partnership with a clinical investigator who can ensure successful trial implementation. Applications also need to show readiness and feasibility in practical terms, such as access to necessary datasets, human samples, cohorts, and other critical reagents. Where FDA involvement is relevant, the submission must demonstrate clinical-trial readiness at the time of application, including access to regulatory-compliant clinical reagents (for example, therapeutics manufactured or handled under appropriate standards), access to an appropriate participant population, realistic and validated recruitment projections, and submission of an IND or IDE to the FDA when applicable. Put simply, this mechanism is meant for teams that are ready to execute, not just plan.

Recruitment planning and accountability are built into the structure of the award. Applicants must provide quarterly enrollment targets across all sites in the Statement of Work (Attachment 4), and awardees will work with USAMRAA to finalize recruitment milestones after selection. Continued funding support is tied to satisfactory progress toward these human subjects recruitment milestones, making enrollment performance a formal condition for staying on track during the project period. In addition, Level 4 applications have an additional review requirement: an invited oral presentation is required as part of the application review process for these projects, reflecting the high-stakes, high-investment nature of the mechanism.

The program also promotes collaboration through an optional Partnering PI model that supports two Principal Investigators working together in a genuinely integrated way. Under this structure, one PI serves as the Initiating PI (handling most submission-related administration) and the other is the Partnering PI, with both expected to contribute substantially to the intellectual development of the project, including the narrative and the statement of work. The intent is balanced, co-led science, where each PI brings distinct, essential expertise and commits an appropriate and roughly comparable level of effort, with funding generally expected to be balanced unless there is a clear justification otherwise. The announcement makes clear that superficial collaborations do not qualify; arrangements where one PI mainly supplies materials while the other carries out nearly all experiments and analyses are not considered responsive to the intent. New PI partnerships are encouraged but not mandatory, and applicants are discouraged from listing the same individual as a Partnering PI on multiple Level 4 applications unless the projects clearly address different research questions. If funded, each PI is named on an individual award within the recipient organization, reinforcing the concept of shared leadership and responsibility.

A strong, appropriately staffed team is another expectation. Applications should include the breadth of breast cancer-relevant expertise needed to carry out a large clinical trial and the surrounding scientific and operational work, which could include clinical operations, biostatistics, regulatory affairs, data management, and recruitment/retention infrastructure, depending on the project design. Beyond scientific staffing, patient-centered input is required through consumer advocate engagement. Each application must include at least two breast cancer consumer advocates who are integrated into the project from planning through execution. Their involvement is expected to be continuous and substantive, spanning areas such as shaping the research question, reviewing study design, oversight, recruitment approaches, and evaluation of project relevance and impact, rather than limited participation like occasional meeting attendance.

These consumer advocates must be individuals diagnosed with breast cancer who are active in advocacy organizations, and they must be independent lay representatives rather than employees of any participating organization on the application. Their role is meant to provide objective perspective on the lived experience, practical relevance, and potential patient impact of the proposed work, and they are expected to have enough familiarity with current breast cancer issues and research to contribute meaningfully. This requirement reinforces the program’s emphasis on research that is not only scientifically compelling but also aligned with patient priorities and real-world clinical adoption.

From an administrative standpoint, the opportunity is offered by the Department of Defense, Department of the Army, through USAMRAA, and supports science and technology/research and development efforts under CFDA 12.420. The funding instruments include grants and cooperative agreements, eligibility is broadly described as unrestricted (with any specific clarifications contained in the full announcement), and the listing indicates an expected single award. The posted record includes a creation date of April 26, 2021 and an original closing date of October 5, 2021, which is important for understanding the timing of that particular solicitation, even though similar opportunities may reappear in future cycles under updated announcements.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Breast Cancer, Breakthrough Award Level 4" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 26, 2021.
• Applicants must submit their applications by Oct 05, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 BCRP BTA4 2

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: